Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis.

Area of Science:

• Health economics
• Clinical trial methodology
• Rare disease research

Background:

• Duchenne muscular dystrophy (DMD) is a severe, life-limiting orphan disease with emerging treatments.
• Pricing and reimbursement decisions for new health technologies often require evidence of value for money.

Purpose of the Study:

• To develop and compare cost-effectiveness models for Duchenne muscular dystrophy (DMD).
• To establish a model based on the DMDSAT, a novel scale for measuring disease progression.
• To compare this new model with two alternative structures for economic evaluations.

Main Methods:

• Three Markov cohort state-transition models were constructed for cost-effectiveness evaluation in a UK setting.
• Model I utilized the DMDSAT scale; Model II used clinical care guideline stages; Model III focused on ventilation status.
• Model structures were developed in collaboration with three DMD experts.

Main Results:

• All three models demonstrated good validity in terms of technique, disease representation, data, and outcomes.
• Lifetime direct medical costs for standard of care ranged from £217,510 to £284,640.
• Total costs varied between £624,240 and £713,840, with quality-adjusted life-years between 5.96 and 7.17.

Conclusions:

• A novel cost-effectiveness model for Duchenne muscular dystrophy (DMD) treatments, based on the DMDSAT, has been developed.
• This model, alongside two alternative frameworks, provides valuable tools for economic evaluations.
• Findings will aid health technology assessments and economic programs for future DMD therapies.